...
首页> 外文期刊>FEBS Letters >Functional phage display of leech‐derived tryptase inhibitor (LDTI): construction of a library and selection of thrombin inhibitors
【24h】

Functional phage display of leech‐derived tryptase inhibitor (LDTI): construction of a library and selection of thrombin inhibitors

机译:水ech类胰蛋白酶抑制剂(LDTI)的功能噬菌体展示:库的构建和凝血酶抑制剂的选择

获取原文
   

获取外文期刊封面封底 >>

       

摘要

>The recombinant phage antibody system pCANTAB 5E has been used to display functionally active leech-derived tryptase inhibitor (LDTI) on the tip of the filamentous M13 phage. A limited combinatorial library of 5.2×104 mutants was created with a synthetic LDTI gene, using a degenerated oligonucleotide and the pCANTAB 5E phagemid. The mutations were restricted to the P1–P4′ positions of the reactive site. Fusion phages and appropriate host strains containing the phagemids were selected after binding to thrombin and DNA sequencing. The variants LDTI-2T (K8R, I9V, S10, K11W, P12A), LDTI-5T (K8R, I9V, S10, K11S, P12L) and LDTI-10T (K8R, I9L, S10, K11D, P12I) were produced with a Saccharomyces cerevisiae expression system. The new inhibitors, LDTI-2T and -5T, prolong the blood clotting time, inhibit thrombin (K i 302 nM and 28 nM) and trypsin (K i 6.4 nM and 2.1 nM) but not factor Xa, plasma kallikrein or neutrophil elastase. The variant LDTI-10T binds to thrombin but does not inhibit it. The relevant reactive site sequences of the thrombin inhibiting variants showed a strong preference for arginine in position P1 (K8R) and for valine in P1′ (I9V). The data indicate further that LDTI-5T might be a model candidate for generation of active-site directed thrombin inhibitors and that LDTI in general may be useful to generate specific inhibitors suitable for a better understanding of enzyme-inhibitor interactions.
机译:>重组噬菌体抗体系统pCANTAB 5E已用于在丝状M13噬菌体尖端展示功能活性的水ech类胰蛋白酶抑制剂(LDTI)。使用简并的​​寡核苷酸和pCANTAB 5E噬菌粒,使用合成的LDTI基因创建了一个5.2×10 4 突变体的有限组合文库。突变仅限于反应位点的P1-P4'位置。在与凝血酶结合和DNA测序后,选择融合噬菌体和含有噬菌粒的合适宿主菌株。 LDTI-2T(K8R,I9V,S10,K11W,P12A),LDTI-5T(K8R,I9V,S10,K11S,P12L)和LDTI-10T(K8R,I9L,S10,K11D,P12I)的变体酿酒酵母表达系统。新型抑制剂LDTI-2T和-5T可以延长血液凝固时间,抑制凝血酶( K i 302 nM和28 nM)和胰蛋白酶( K < / em> i 6.4 nM和2.1 nM),但不包括因子Xa,血浆激肽释放酶或嗜中性粒细胞弹性蛋白酶。变体LDTI-10T与凝血酶结合但不抑制它。凝血酶抑制变体的相关反应位点序列表现出强烈的优先选择P1(K8R)的精氨酸和P1'(I9V)的缬氨酸。数据进一步表明,LDTI-5T可能是产生活性位点定向的凝血酶抑制剂的候选模型,而LDTI通常可用于产生适合于更好地理解酶-抑制剂相互作用的特异性抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号